Billion-dollar baby: Biotech still on a roll with VC funds

The latest survey from the National Venture Capital Association shows that biotechnology is still on a roll with investors. The association tracked 99 biotech deals in the third quarter which were worth $1.1 billion. Frazier Healthcare Ventures is so pumped about developers it's reserved half of its latest $600 million fund for biotech deals. An ongoing obstacle: A reluctance among VCs to back early-stage ventures. Most worrisome trend: The prospect that a new group of politicos in charge of healthcare legislation in Washington DC will chill the life sciences field with talk of reform.

- read the report from BioWorld on venture capital trends

Related Articles:
Venture capitalists bet big on nanotechnology. Report
Bill could improve funding for small biotechs. Report
Biotech sees big money from corporate players. Report
The Top 5 VC deals of the first half of 2007. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.